After a strong first half that almost put the pre-recession days of 2007 within reach, a steep decline in third-quarter biotech fundraising had most folks reaching for the TUMS. Read More
United Therapeutics Corp., of Silver Spring, Md., intends to offer $210 million worth of convertible senior notes due 2016 in a private placement. An additional $40 million worth of notes will be available to cover overallotments. Read More
Genesis Biopharma Inc., of Los Angeles, has entered a license agreement with the National Institutes of Health for 43 patents and patent applications relating to adoptive cell therapy with autologous tumor infiltrating lymphocytes. Read More
Pevion Biotech AG, of Bern, Switzerland, reported the latest results from its ongoing clinical study of volunteers vaccinated with the intramuscular high dose of Candida vaccine PEV7, showing high levels of specific antibodies and a 100 percent mucosal immune response rate. Data showed significantly increased immunogenicity over the previously vaccinated low-dose group and confirmed the safety profile customary for virosome-delivered vaccines. Read More
Privately held GlycoMimetics Inc. landed its first big pharma partnership, licensing rights to pan-selectin antagonist GMI-1070 to Pfizer Inc. for further development in the orphan indication of sickle cell crisis, as well as other indications. Read More
LONDON – The UK biopharmaceutical industry is preparing a new defense against the incursions that health technology assessments (HTA) are making on its ability to get reimbursement for some drugs and the full price for others, turning to real-world data to demonstrate the value of its products. Read More
